Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. „J Med Chem”. 23 (49), s. 6819-6832, 2006. DOI: 10.1021/jm060727j. PMID: 17154512.
P. Mendiratta, E. Mostaghel, J. Guinney, A.K. Tewari i inni. Genomic strategy for targeting therapy in castration-resistant prostate cancer. „J Clin Oncol”. 27 (12), s. 2022-2029, 2009. DOI: 10.1200/JCO.2008.17.2882. PMID: 19289629.
E.Y. Yu, G. Wilding, E. Posadas, M. Gross i inni. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. „Clin Cancer Res”. 15 (23), s. 7421-7428, 2009. DOI: 10.1158/1078-0432.CCR-09-1691. PMID: 19920114.
A. Potti, H.K. Dressman, A. Bild, R.F. Riedel i inni. Genomic signatures to guide the use of chemotherapeutics. „Nat Med”. 12 (11), s. 1294-1300, 2006. DOI: 10.1038/nm1491. PMID: 17057710.
Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. „J Med Chem”. 23 (49), s. 6819-6832, 2006. DOI: 10.1021/jm060727j. PMID: 17154512.
P. Mendiratta, E. Mostaghel, J. Guinney, A.K. Tewari i inni. Genomic strategy for targeting therapy in castration-resistant prostate cancer. „J Clin Oncol”. 27 (12), s. 2022-2029, 2009. DOI: 10.1200/JCO.2008.17.2882. PMID: 19289629.
E.Y. Yu, G. Wilding, E. Posadas, M. Gross i inni. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. „Clin Cancer Res”. 15 (23), s. 7421-7428, 2009. DOI: 10.1158/1078-0432.CCR-09-1691. PMID: 19920114.
A. Potti, H.K. Dressman, A. Bild, R.F. Riedel i inni. Genomic signatures to guide the use of chemotherapeutics. „Nat Med”. 12 (11), s. 1294-1300, 2006. DOI: 10.1038/nm1491. PMID: 17057710.